PRESS RELEASE: Source PR Newswire
The FDA announced approval of a 1-hour swab test to detect MRSA on Monday, December 19th. MRSA (methicillin-resistant Staphylococcus aureus) is a type of staph bacteria that is resistant to many antibiotics that has posed significant threats to patients and athletes for over a decade. The announcement of approval for the new test, Xpert® MRSA NxG, for MRSA produced by Cepheid by the U.S. Food & Drug Administration is a step forward in fighting the harmful and easily transmitted bacteria.
MRSA is spread by direct contact and is a risk for athletes and hospital patients. The bacteria must be cultured to know if it is in fact MRSA. The new swab test manufactured by Cepheid will help improve the speed of results for patients thought to have MRSA. Speed will result in faster treatment to aid in stopping the bacteria spreading in contact.
“MRSA surveillance remains a critical infection prevention activity for healthcare facilities and one that is challenged by the continued evolution of target sequences within MRSA,” said Fred Tenover, PhD, Cepheid’s vice president for scientific affairs. “Fortunately, our global MRSA surveillance initiative has helped us keep ahead of the curve by alerting us to the emergence of novel strain types, enabling us to design a more comprehensive assay that takes into account major shifts, like the emergence of mecC, as well as more subtle changes in the SCCmec targets.”
Cepheid is committed to the fight against the spread of multidrug-resistant organisms. Xpert® MRSA NxG will begin shipping in December. For more information on Cepheid’s GeneXpert® Systems or the complete menu of Xpert tests, visit www.cepheidinternational.com.